Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Unum Therapeutics Inc (NASDAQ:UMRX) shares were under pressure Wednesday following a clinical trial update provided by the company late Tuesday.
What Happened
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The FDA has imposed a clinical hold on the Phase 1 ATTCK-20-2 trial that evaluated ACTR087 in combination with Roche Holdings AG Basel ADR (OTC:RHHBY)'s rituximab following lymphodepleting chemotherapy with fludarabine and cyclophosphamide in patients with relapsed/refractory CD20+ B cell non-Hodgkin lymphoma.
A clinical hold is an order issued by the FDA to delay an ongoing clinical trial or altogether suspend it; enrolled patients may not be given the investigational drug and new patient enrollment is halted.
The FDA action comes after Unum submitted a safety report regarding one patient in cohort 3 of the trial who experienced serious adverse events that included Grade 3 neurotoxicity, cytomegalovirus infection and Grade 4 respiratory distress.
Why It's Important
Unum, which provides curative T-cell therapies to treat a broad range of cancer patients, went public in May 2018.
Since closing at $12.90, a 24% premium over its IPO price of $12, the stock has lost much of its value.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
In its S-1 filing ahead of the IPO, Unum disclosed two deaths in its ACTR087 trial, with one resulting from enterococcal sepsis related to the investigational drug and another from unrelated sepsis.
The company said it has deprioritized its onetime lead product candidate ACTR087 and is now focusing on its new ACTR construct ACTR707 in combination with rituximab for the same indication.
What’s Next
Unum said the FDA has agreed that patients who previously received ACTR087 and have clinical responses may continue to receive rituximab infusions, with continued monitoring for adverse events.
The company said it will work closely with the FDA to further review these events and report data from the ATTCK-20-2 trial at the end of 2019.
Unum shares were trading higher by 4.57% at $2.29 at the time of publication Wednesday.
Related Links:
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.